Previous studies have established that reduced KIT expression, in conjunction with tyrosine kinase inhibitors, can decrease proliferation and increase apoptosis in the mastocytosis cell line HMC1.1, which carries the KITV560G activating mutation [50]. Here, KIT is linked to mastocytosis.